RxDoctor Payments Data

Sierra Norwood

Gerontology · Monroe, LANPI 1568028611

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 29 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 13 manufacturers reported payments, led by AstraZeneca at 29.4% of the total. 2025 is the largest year on record at $483, more than ten times the $30 reported in 2023.

$680in general payments, 2019–2025

Across 29 payments — averaging $23.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$200
  • Amgen$126
  • AbbVie$74
  • Lilly USA, LLC$53
  • Supernus Pharmaceuticals, Inc.$42
  • Abbott$33
  • plus $151 from 7 others

What the payments were for

  • Food & beverage$680100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$680 in reported general payments places this provider in the 55th percentile of 64 gerontology providers in Louisiana.

See all gerontology providers in Louisiana

Medicare billing

Part B allowed, 2024
$14,061
Medicare patients
45
Services billed
667

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate22$30,053
OzempicSemaglutide29$28,349
JardianceEmpagliflozin22$21,140
MounjaroTirzepatide21$19,313
EliquisApixaban20$13,797
LinzessLinaclotide17$9,608
EntrestoSacubitril/Valsartan11$7,499
Lantus SolostarInsulin Glargine,hum.Rec.Anlog16$3,304
Albuterol Sulfate HfaAlbuterol Sulfate76$2,958
Atorvastatin Calcium184$1,810
Diclofenac Sodium44$1,800
Gabapentin118$1,634
Celecoxib18$1,409
FenofibrateFenofibrate Nanocrystallized37$1,404
Oxybutynin Chloride ErOxybutynin Chloride26$1,212

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$20$28,34929 claims
Boehringer IngelheimJardiance$33$21,14022 claims
Lilly USA, LLCMounjaro$53$19,31321 claims
PfizerEliquis$24$13,79720 claims
AbbVieLinzess$74$9,60817 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 64 gerontology providers in Louisiana.

Other gerontology in Monroe

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →